aTyr Pharma is a public biotherapeutics company (NASDAQ: LIFE) that is focused on researching the extracellular functionality and signalling pathways of tRNA synthetases.
The company’s lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.The company was founded in 2005 and is headquartered in San Diego, CA, and led by CEO Sanjay S. Shukla, M.D., M.S.
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 33.11M; Volume: 35.17K; AvgVol 3m: 104.74K; Beta: –;
P/E: –; EPS: -3.43; EPS growth quarter/prev quarter: 61.80%;
EPS growth this year: 56.40%; EPS growth past 5 years: 14.50%;
EPS ttm: -3.44;
P/S: 04.01; P/B: 0.85; P/Cashflow: 0.83; P/FCF: ;
Sales: 8.57M; Sales growth quarter/prev quarter: 100.00%; Sales growth past 5 years: ;
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -35.90%; ROE – return on equity: -51.70%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.14;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.30%; Insider Transactions:-18.47%;
Institutional Ownership: 64.10%; Institutional Transactions: 5.41%;
Data update: 07/10/2020.